凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
广誉远(600771)公告正文

广誉远:2013年第三季度报告

公告日期 2013-10-30
股票简称:广誉远 股票代码:600771
广誉远中药股份有限公司
          6007712013 年第三季度报告
    二○一三年十月二十九日
                                                           广誉远中药股份有限公司 2013 年第三季度报告
       一、重要提示
       1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
       1.2 公司全体董事出席董事会会议。
       1.3
             公司负责人姓名                              董事长张斌
             主管会计工作负责人姓名                      财务总监傅淑红
             会计机构负责人(会计主管人员)姓名          财务经理傅淑红
       公司负责人董事长张斌、主管会计工作负责人财务总监傅淑红及会计机构负责人(会计主管人员)财务经理傅淑红保证季度报告中财务报表的真实、准确、完整。
       1.4 公司第三季度报告中的财务报表未经审计。
       二、公司主要财务数据和股东变化
       2.1 主要财务数据
                                                                                          单位:元
                                                                                本报告期末比上年
                                        本报告期末            上年度末
                                                                                   度末增减(%)
       总资产                         495,497,860.84        721,210,307.52                   -31.30
       归属于上市公司股东的净资产      47,326,327.94         21,209,740.20                   123.13
                                      年初至报告期末       上年初至上年报
                                                                               比上年同期增减(%)
                                        (1-9 月)         告期末(1-9 月)
       经营活动产生的现金流量净额      23,858,802.21         -6,453,148.44                   469.72
                                      年初至报告期末       上年初至上年报
                                                                               比上年同期增减(%)
                                        (1-9 月)         告期末(1-9 月)
       营业收入                       187,908,906.11        201,005,033.95                     -6.52
       归属于上市公司股东的净利润       1,017,493.11        -69,492,412.25                   101.46
       归属于上市公司股东的扣除非
                                                            -65,707,532.19                    49.99
       经常性损益的净利润              -32,861,410.01
       加权平均净资产收益率(%)                  2.97
                                                            广誉远中药股份有限公司 2013 年第三季度报告
    基本每股收益(元/股)                            0.004                 -0.29                   101.38
    稀释每股收益(元/股)                            0.004                 -0.29                   101.38注:因上年同期公司净利润、净资产同为负数,故上年同期未计算净资产收益率等相关指标。扣除非经常性损益项目和金额
                                                                                           单位:元
                                                             本期金额           年初至报告期金额
                     项       目
                                                            (7-9月)               (1-9月)
    非流动性资产处置损益                                           62,944.94            -312,772.17
    计入当期损益的政府补助(与公司正常经营业
    务密切相关,符合国家政策规定、按照一定标                      578,500.00           1,860,000.00
    准定额或定量持续享受的政府补助除外)
    债务重组损益                                                4,694,342.32          33,818,098.74
    除上述各项之外其他营业外收入和支出                           -848,011.35            -664,756.19
    所得税影响额                                                    2,995.50            -12,115.73
    少数股东权益影响额(税后)                                    99,743.84            -809,551.53
                       合计                                   4,590,515.25          33,878,903.122.2 截至报告期末的股东总数、前十名股东、前十名无限售条件股东的持股情况表
                                                                                              单位:股
          报告期股东总数                                             19141
                                         前十名股东持股情况
                                                                                  持有有
                                                   持股比                                     质押或冻结
          股东名称                 股东性质                    持股总数         限售条件
                                                   例(%)                                    的股份数量
                                                                                股份数量
    西安东盛集团有限公司      境内非国有法人           22.17     54,048,265     54,048,265       54,048,265
    中国长城资产管理公司      国有法人                  5.00     12,200,000                          无
    鞍山钢铁集团公司          国有法人                  3.80       9,270,141                         无
    郑文平                    境内自然人                1.88       4,584,971                         无中信证券股份有限公司
    约定购回式证券交易专      其他                      1.22       2,968,000                         无用证券账户
    景旻                      境内自然人                1.21       2,944,522                         无
    新华信托股份有限公司      其他                      1.04       2,545,625                         无
                                                         广誉远中药股份有限公司 2013 年第三季度报告-普利宏铭 1 号
    东方证券股份有限公司      其他                   1.03       2,499,872                       无
    刘国                      境内自然人             0.94       2,300,000                       无
    山东创润投资有限公司      其他                   0.85       2,070,000                       无
                             前十名无限售条件流通股股东持股情况
    股东名称                                        持有无限售条件股份数量               股份种类
    中国长城资产管理公司                                              12,200,000       人民币普通股
    鞍山钢铁集团公司                                                   9,270,141       人民币普通股
    郑文平                                                             4,584,971       人民币普通股中信证券股份有限公司约定购回式证券交
                                                                    2,968,000       人民币普通股易专用证券账户
    景旻                                                               2,944,522       人民币普通股
    新华信托股份有限公司-普利宏铭 1 号                                2,545,625       人民币普通股
    东方证券股份有限公司                                               2,499,872       人民币普通股
    刘国                                                               2,300,000       人民币普通股
    山东创润投资有限公司                                               2,070,000       人民币普通股
    廖润华                                                             1,784,927       人民币普通股
                                                公司未知上述股东是否存在关联关系,也未知其是
    上述股东关联关系或一致行动的说明               否属于《上市公司收购管理办法》中规定的一致行
                                                动人。三、重要事项3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
    √适用       □不适用1、报告期内公司资产、负债项目同比发生重大变动项目及主要原因
                                                                                       单位:元
    项目               期末数             期初数                 增减额         增减比例(%)
    预付款项             58,803,875.00       35,447,829.71          23,356,045.29             65.89
    其他应收款           75,297,675.40      300,390,055.54        -225,092,380.14            -74.93
    短期借款             15,162,875.33       28,317,924.53         -13,155,049.20            -46.45
    应付利息              1,701,405.48        5,235,298.09          -3,533,892.61            -67.50
    其他应付款          144,675,964.39      329,898,053.13        -185,222,088.74            -56.15
                                                      广誉远中药股份有限公司 2013 年第三季度报告
    (1)预付账款比期初增加 2336 万元,增幅为 65.89%,主要因为报告期公司不再将东盛友邦制药有限公司(以下简称“东盛友邦”)纳入合并报表范围,对其的预付款项为 2114 万元;
    (2)其他应收款比期初减少 22509 万元,减幅为 74.93%,主要因为:
    ① 报告期内公司收到了陕西王府实业有限公司(以下简称“王府实业”)欠付的资产购买款 14600 万元;
    ② 报告期内西安市中级人民法院将剩余 6588.18 万元的青海制药集团有限公司股权拍卖款支付给了长城资产管理公司(以下简称“长城公司”)等债权人。
    (3)短期借款和应付利息分别比期初减少 1316 万元和 353 万元,减幅为 46.45%和 67.50%,主要因为本报告期公司与石嘴山银行股份有限公司(以下简称“石嘴山银行”)签订债务减让协议,在公司偿还其 700 万元本金后,石嘴山银行相应减免公司债务利息 469.43 万元所致;同时本报告期不再将东盛友邦纳入合并报表范围,相应减少其短期借款 500 万元。
    (4)其他应付款比期初减少 18522 万元,减幅为 56.15%,主要因为报告期内公司偿还了欠付长城公司金融债务 15456.46 万元以及河北金牛化工股份有限公司(以下简称“金牛化工”)不再行使就原沧州化学工业股份有限公司与公司及公司控股子公司陕西东盛医药有限责任公司(以下简称“东盛医药”)因担保代偿而形成的追偿权 2912.38万元。
    2、报告期公司经营状况同比发生重大变动的说明
                                                                                   单位:元
         项目      2013 年 1-9 月    2012 年 1-9 月            增减额          增减比例(%)
    财务费用           4,490,768.21     47,432,931.67         -42,942,163.46            -90.53
    资产减值损失          808,012.02     6,445,339.40          -5,637,327.38            -87.46
    营业外收入        36,108,518.94      4,159,052.22          31,949,466.72            768.19
    营业外支出         1,407,948.56      8,116,896.99          -6,708,948.43            -82.65
    营业利润         -34,473,575.68    -67,574,116.90          33,100,541.22             48.98
    利润总额              226,994.70   -71,531,961.67          71,758,956.37            100.32
    (1)财务费用较上年同期减少 4294 万元,减幅 90.53%,主要是因为上年度长城公司收购了建行西安雁塔路支行等金融机构对公司的债权后,与公司及控股子公司安徽
                                                         广誉远中药股份有限公司 2013 年第三季度报告东盛制药有限公司(以下简称“安徽东盛”)、东盛医药进行了债务重组,故本报告期,公司不再计提相关银行借款利息费用;
    (2)资产减值损失较上年同期减少 564 万元,减幅 87.46%,主要因为本报告期公司对销售环节商业客户资信实行严格控制,保证货款尽可能在信用期内收回,同时加大以前年度应收款项的清收工作所致;
    (3)营业外收入较上年同期增加 3195 万元,增幅 768.19%,主要因为报告期金牛化工不再行使对公司的担保追偿权 2912.38 万元;以及与石嘴山银行进行债务重组,免除了公司的债务利息 469.43 万元,公司确认了上述两项豁免收益所致;
    (4)营业外支出较上年同期减少 671 万元,减幅 82.65%,主要因为上年同期公司支付中信银行石家庄分行 740 万元以免除债务担保责任所致;
    (5)营业利润、利润总额分别较上年同期增加 3310 万元、7176 万元,增幅分别为 48.98%和 100.32%,主要因为报告期财务费用减少以及确认相关债务豁免收益所致。
    3、报告期公司现金流量同比发生变动的说明
                                                                                         单位:元
                项目              2013 年 1-9 月    2012 年 1-9 月       增减额        增减比例(%)
    经营活动产生的现金流量净额    23,858,802.21     -6,453,148.44     30,311,950.65         469.72
    投资活动产生的现金流量净额   128,657,029.34      4,534,560.85   124,122,468.49         2737.25
    筹资活动产生的现金流量净额   -140,416,661.45    -2,330,640.38   -138,086,021.07       -5924.81
    (1)经营活动产生的现金流量净额较上年同期增加 3031 万元,增幅为 469.72%,主要因为本报告期公司收到长城公司返还的 6330 万元及收回其他款项所致;
    (2)投资活动产生的现金流量净额较上年同期增加 12412 元,增幅为 2737.25%,主要是因为本报告期公司收到了上年度王府实业欠付的资产购买款 14600 万元;
    (3)筹资活动产生的现金流量净额较上年同期减少 13809 万元,减幅为 5924.81%,主要是因为:
    ① 本报告期公司将收到的资产转让款 14600 万元支付给长城公司;
    ② 本报告期公司支付给国家开发银行吉林分行 911 万元用以履行对兰宝科技信息股份公司银行借款的担保责任。
                                              广誉远中药股份有限公司 2013 年第三季度报告
    3.2 重要事项进展情况及其影响和解决方案的分析说明
    √适用   □不适用
    2012 年度,负责公司审计工作的中磊会计师事务所为公司出具了带强调事项的无保留意见审计报告,并出具了专项说明。审计意见所涉及的强调事项为“持续经营能力存在不确定性”。
    针对上述事项,公司 2013 年继续积极推进债务重组、进一步优化整合医药资源,同时围绕“创新、求实、增效、共赢”的主题,全力提升运营效率,构建企业核心竞争力,以确保公司的持续、健康发展。
    1、债务重组
    (1)2013 年 6 月 13 日,公司及其控股子公司东盛医药、安徽东盛分别与长城公司签署三份《债务减让协议》,根据协议的约定,公司及其子公司向其偿还 15456.46 万元后,长城公司相应减免公司债务利息 2525.54 万元。
    (2)2013 年 9 月 13 日,公司与石嘴山银行签署《债务减让协议》,根据协议的约定,公司在偿还其 700 万元后,石嘴山银行相应减免公司债务利息 469.43 万元。
    2、优化整合医药资源,全力提升运营效率
    2013 年,公司进一步整合现有医药资源,全力提升运营效率:
    (1)公司确立了以中兴广誉远国药公司、创新传承广誉远国药文化、造福人民健康事业为使命,将打造养生精品中药、打造经典国药事业单元,打造高尚养生酒和其他健康养生产品事业单元,打造优秀普药事业单元作为发展的重要战略方向,进一步整合现有医药资源,于 2013 年 6 月引进战略投资者对东盛友邦进行增资扩股,以加速东盛友邦主营业务发展,提高其可持续发展能力,最终实现东盛友邦股东价值的最大化。
    (2)公司以拥有龟龄集、定坤丹、安宫牛黄丸等传统中药为核心的广誉远国药为战略发展基石,认真总结、深入分析市场变化,结合公司产品的特点,及时调整营销思路,逐步恢复产品线,并致力于品牌复兴,重点发展核心产品,以“精品中药+保健酒+传统中药”三驾马车拉动广誉远国药销售,同时积极整合公司优势普药资源,全力提升运营效率。
    3.3 公司及持股 5%以上的股东承诺事项履行情况
    □适用   √不适用
                                             广誉远中药股份有限公司 2013 年第三季度报告
    3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
    □适用   √不适用
    四、附录(附后)
                                                       广誉远中药股份有限公司
                                                       董事长:
                                                                      张 斌
                                                        二○一三年十月二十九日
                                                                 广誉远中药股份有限公司 2013 年第三季度报告
                                               资产负债表
    编制单位:广誉远中药股份有限公司               2013 年 9 月 30 日                            金额单位:元
                                          合   并                                   母公司
        资      产
                               期末数                 年初数              期末数               年初数流动资产:
    货币资金                    19,103,108.75           17,325,938.65        2,777,542.82        12,134,236.40交易性金融资产
    应收票据                     4,975,493.08            5,585,099.13          655,527.00
    应收账款                    93,476,810.27           82,850,998.73       16,670,439.97        13,862,825.23
    预付款项                    58,803,875.00           35,447,829.71        9,577,768.93         9,161,368.22应收利息应收股利
    其他应收款                  75,297,675.40          300,390,055.54       65,258,801.57       285,176,745.16
    存货                        64,396,458.94           73,436,803.21        7,544,958.70         6,654,773.65一年内到期的非流动资产其他流动资产
    流动资产合计               316,053,421.44          515,036,724.97      102,485,038.99       326,989,948.66非流动资产:可供出售金融资产持有至到期投资
    长期股权投资                      35,321.55              35,321.55      96,689,144.76       111,054,383.64投资性房地产
    固定资产                   133,996,189.76          159,965,572.00       49,952,451.19        54,027,981.86
    在建工程                     9,514,710.41            5,999,434.13        9,494,430.41         5,979,154.13工程物资固定资产清理生产性生物资产油气资产
    无形资产                    16,418,743.51           20,693,780.70        3,461,803.06         3,529,497.37开发支出
    商誉                        11,775,418.18           11,775,418.18长期待摊费用
    递延所得税资产               7,704,055.99            7,704,055.99其他非流动资产
    非流动资产合计             179,444,439.40          206,173,582.55      159,597,829.42       174,591,017.00
    资产总计                   495,497,860.84          721,210,307.52      262,082,868.41       501,580,965.66
                                                                       广誉远中药股份有限公司 2013 年第三季度报告
                                             资产负债表(续)
    编制单位:广誉远中药股份有限公司                     2013 年 9 月 30 日                            金额单位:元
                                                    合    并                                  母公司
        负债和所有者权益
                                           期末数                  年初数            期末数              年初数流动负债:
    短期借款                                 15,162,875.33         28,317,924.53      4,832,972.40        12,132,972.40交易性金融负债
    应付票据                                                           46,500.00
    应付账款                                 71,234,494.24         85,173,840.68    383,073,247.13    397,830,725.74
    预收款项                                 20,739,172.24         29,203,267.81    118,380,644.57    168,958,226.34
    应付职工薪酬                             30,043,948.15         27,930,696.05      1,912,751.62         2,589,415.01
    应交税费                                 66,896,110.14         89,343,295.36      1,100,497.96        16,125,443.29
    应付利息                                  1,701,405.48          5,235,298.09      1,540,444.47         5,186,553.11应付股利
    其他应付款                             144,675,964.39         329,898,053.13     51,497,023.52    191,234,281.58一年内到期的非流动负债其他流动负债
    流动负债合计                           350,453,969.97         595,148,875.65    562,337,581.67    794,057,617.47非流动负债:长期借款应付债券长期应付款专项应付款
    预计负债                                 37,397,459.42         46,509,459.42     37,397,459.42        46,509,459.42递延所得税负债
    其他非流动负债                           28,059,142.87         28,059,142.88     10,000,000.00        10,000,000.00
    非流动负债合计                           65,456,602.29         74,568,602.30     47,397,459.42        56,509,459.42
    负债合计                               415,910,572.26         669,717,477.95    609,735,041.09    850,567,076.89所有者权益(或股东权益):
    实收资本                               243,808,438.00         243,808,438.00    243,808,438.00    243,808,438.00
    资本公积                               415,449,599.11         390,350,504.48    396,156,422.03    387,030,891.29
    盈余公积                                 29,615,319.69         29,615,319.69
    未分配利润                             -641,547,028.86        -642,564,521.97   -987,617,032.71   -979,825,440.52
    归属于母公司所有者权益合计               47,326,327.94         21,209,740.20    -347,652,172.68   -348,986,111.23
    少数股东权益                             32,260,960.64         30,283,089.37
    所有者权益(或股东权益)合计             79,587,288.58         51,492,829.57    -347,652,172.68   -348,986,111.23
    负债和所有者权益(或股东权益)总计     495,497,860.84         721,210,307.52    262,082,868.41    501,580,965.66
    法定代表人: 张斌                     主管会计工作负责人:傅淑红                      会计机构负责人:傅淑红
                                                                         广誉远中药股份有限公司 2013 年第三季度报告
                                                       利润表
    编制单位:广誉远中药股份有限公司                            2013 年 1-9 月                          金额单位:元
                                                       合     并                               母公司
              项     目
                                              本期数                 上期数           本期数              上期数
    一、营业收入                              187,908,906.11        201,005,033.95    29,912,217.11        29,250,007.56
    减:营业成本                               82,894,251.99        101,390,967.21    13,113,421.69        14,797,828.53
    营业税金及附加                              2,344,511.84           2,293,288.04      326,420.23          372,054.76
    销售费用                                   74,368,763.24          62,385,917.54   11,962,964.09        11,310,324.51
    管理费用                                   57,476,174.49          48,630,706.99   16,704,518.13        16,443,562.04
    财务费用                                    4,490,768.21          47,432,931.67    2,348,582.28        28,729,687.37
    资产减值损失                                 808,012.02            6,445,339.40加:公允价值变动收益投资收益其中:对联营企业和合营企业的投资收益
    二、营业利润                              -34,473,575.68        -67,574,116.90    -14,543,689.31   -42,403,449.65
    加:营业外收入                             36,108,518.94           4,159,052.22   21,500,718.55           11,957.79
    减:营业外支出                              1,407,948.56           8,116,896.99      383,382.55         7,400,354.88
    其中:非流动资产处置损失                     375,717.11             190,693.17
    三、利润总额                                 226,994.70         -71,531,961.67     6,573,646.69    -49,791,846.74
    减:所得税费用                               230,814.96             232,085.18
    四、净利润                                     -3,820.26        -71,764,046.85     6,573,646.69    -49,791,846.74
    归属于母公司所有者的净利润                  1,017,493.11        -69,492,412.25
    少数股东损益                               -1,021,313.37          -2,271,634.60五、每股收益
    (一)基本每股收益                                0.004                   -0.29
    (二)稀释每股收益                                0.004                   -0.29
    法定代表人: 张斌                       主管会计工作负责人:傅淑红                      会计机构负责人:傅淑红
                                                                       广誉远中药股份有限公司 2013 年第三季度报告
                                                      利润表
    编制单位:广誉远中药股份有限公司                           2013 年 7-9 月                             金额单位:元
                                                      合    并                               母公司
              项     目
                                             本期数              上年同期数         本期数            上年同期数
    一、营业收入                              57,702,955.84         73,068,491.33   10,474,168.71     10,285,189.03
    减:营业成本                              24,412,611.10         34,888,925.24    5,407,238.33        6,327,782.43
    营业税金及附加                               729,840.71           831,280.26       110,124.75          119,305.96
    销售费用                                  25,340,883.15         22,083,509.69    4,329,353.87        2,969,435.85
    管理费用                                  18,722,467.83         16,127,187.64    5,710,476.44        6,722,981.11
    财务费用                                   1,085,925.19         14,489,436.37      318,290.65        9,557,173.19
    资产减值损失                                 -72,619.77           245,363.09加:公允价值变动收益投资收益其中:对联营企业和合营企业的投资收益
    二、营业利润                             -12,516,152.37        -15,597,210.96   -5,401,315.33    -15,411,489.51
    加:营业外收入                             4,957,863.58          3,798,787.63    4,738,895.48            6,530.00
    减:营业外支出                               470,087.67          7,603,010.89        6,000.00        7,400,000.00
    其中:非流动资产处置损失                                           37,306.38
    三、利润总额                              -8,028,376.46        -19,401,434.22     -668,419.85    -22,804,959.51
    减:所得税费用                                22,967.65
    四、净利润                                -8,051,344.11        -19,401,434.22     -668,419.85    -22,804,959.51
    归属于母公司所有者的净利润                -7,886,902.17        -17,846,271.40
    少数股东损益                                -164,441.94         -1,555,162.82五、每股收益
    (一)基本每股收益                                -0.03                 -0.07
    (二)稀释每股收益                                -0.03                 -0.07
    法定代表人: 张斌                       主管会计工作负责人:傅淑红                    会计机构负责人:傅淑红
                                                                     广誉远中药股份有限公司 2013 年第三季度报告
                                                   现金流量表
    编制单位:广誉远中药股份有限公司                           2013 年 1-9 月                         金额单位:元
                                                         合并                                母公司
                                                本期数            上期数            本期数              上期数一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                216,381,602.98   218,658,371.79     32,189,679.28    25,435,309.36
    收到的税费返回                                  533,827.18       321,505.97
    收到的其他与经营活动有关的现金               81,642,018.57     10,348,330.00    73,642,018.57
    现金流入小计                                298,557,448.73   229,328,207.76    105,831,697.85    25,435,309.36
    购买商品、接受劳务支付的现金                106,863,224.77   122,118,845.14     31,406,767.75        8,031,216.44
    支付给职工以及为职工支付的现金               48,812,104.03     38,600,834.98    12,153,637.94    10,213,198.96
    支付的各项税费                               30,844,554.16     18,733,064.00      5,118,169.95       4,983,260.93
    支付的其他与经营活动有关的现金               88,178,763.56     56,328,612.08    48,822,109.72        8,452,536.18
    现金流出小计                                274,698,646.52   235,781,356.20     97,500,685.36    31,680,212.51
    经营活动产生的现金流量净额                   23,858,802.21     -6,453,148.44     8,331,012.49    -6,244,903.15二、投资活动产生的现金流量:
    取得投资收益所收到的现金                                        5,469,529.51                         5,469,529.51处置固定资产、无形资产和其他长期
                                             146,219,617.00                     146,219,617.00资产而收回的现金净额收到的其他与投资活动有关的现金
    现金流入小计                                146,219,617.00      5,469,529.51   146,219,617.00        5,469,529.51
    购建固定资产所支付的现金                      3,151,766.41       934,968.66      1,695,642.24         422,370.47投资支付的现金
    支付的其他与投资有关的现金                   14,410,821.25                      14,410,821.25
    现金流出小计                                 17,562,587.66       934,968.66     16,106,463.49         422,370.47
    投资活动产生的现金流量净额                  128,657,029.34      4,534,560.85   130,113,153.51        5,047,159.04三、筹资活动产生的现金流量:
    吸收投资收到的现金                            3,000,000.00
    借款所收到的现金                              8,490,000.00     13,070,000.00                         3,800,000.00
    收到的其他与筹资活动有关的现金               26,908,452.42      8,437,600.00    25,308,452.42        8,437,600.00
    现金流入小计                                 38,398,452.42     21,507,600.00    25,308,452.42    12,237,600.00
    偿还债务所支付的现金                         21,645,049.20     14,075,022.81     7,300,000.00        5,084,947.58
    分配股利、利润或偿付利息所支付的现金          2,057,464.67      2,363,217.57       374,712.00         325,038.00
    支付的其他与筹资活动有关的现金              155,112,600.00      7,400,000.00   155,112,600.00        7,400,000.00
    现金流出小计                                178,815,113.87     23,838,240.38   162,787,312.00    12,809,985.58
    筹资活动产生的现金流量净额                 -140,416,661.45     -2,330,640.38   -137,478,859.58        -572,385.58
    四、现金及现金等价物净增加(减少)           12,099,170.10     -4,249,227.97       965,306.42    -1,770,129.69
    加:期初现金及现金等价物余额                  7,003,938.65      9,701,551.60     1,812,236.40        2,706,227.16
    五、期末现金及现金等价物余额                 19,103,108.75      5,452,323.63     2,777,542.82         936,097.47
    法定代表人: 张斌                       主管会计工作负责人:傅淑红                   会计机构负责人:傅淑红
数据加载中...
prevnext
手机查看股票